Background: The cyclic adenosine monophosphate response element-binding proteins (CREB) and their interaction with brain-derived neurotrophic factor (BDNF) are essential elements in signal transduction pathways important for cellular resilience and neuroplasticity. They play a decisive role in the concept of altered neuroplasticity in major depression. We have previously demonstrated that the increase in phosphorylated CREB (pCREB) in T lymphocytes is significantly associated with clinical improvement in patients treated with antidepressants. In the present study, we focused on patients treated only with psychotherapy to exclude direct pharmacological actions. In addition to pCREB, we also measured the BDNF plasma levels. Methods: pCREB in T lymphocytes was determined by Western blot; the BDNF plasma levels with solid-phase ELISA. Psychopathology was evaluated with the Hamilton Rating Scale for Depression (HAMD). Thirty patients meeting DSM-IV criteria for major depressive episodes (MDE) were recruited into this 6-week study. They received interpersonal psychotherapy (IPT) twice weekly. Results: After 6 weeks of IPT, 17 patients responded (reduction of ≥50% of baseline HAMD); after 1 week of treatment pCREB increased significantly compared to the nonresponder group. Measurement of the BDNF plasma levels revealed no differences between the responder and nonresponder groups. Furthermore, the correlations between BDNF plasma levels and pCREB were not significant. Conclusions: The early increase in pCREB is related to treatment response and does not depend on pharmacological interventions or BDNF plasma levels. For the first time, cellular biological markers could be associated with response to psychotherapy.

Keywords:
Depression, CREB phosphorylation, Brain-derived neurotrophic factor, Interpersonal psychotherapy, Response
1.
Duman RS, Malberg J, Thome J: Neural plasticity to stress and antidepressant treatment. Biol Psychiatry 1999;46:1181–1191.
2.
Manji HK, Moore GJ, Rajkowska G, Chen G: Neuroplasticity and cellular resilience in mood disorders. Mol Psychiatry 2000;5:578–593.
3.
Chen B, Dowlatshahi D, MacQueen GM, Wang JF, Young LT: Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol Psychiatry 2001;50:260–265.
4.
Thome J, Sakai N, Shin K, Steffen C, Zhang YJ, Impey S, Storm D, Duman RS: cAMP response element-mediated gene transcription is upregulated by chronic antidepressant treatment. J Neurosci 2000;20:4030–4036.
5.
Coyle JT, Duman RS: Finding the intracellular signaling pathways affected by mood disorder treatments. Neuron 2003;38:157–160.
6.
Koch JM, Kell S, Aldenhoff JB: Differential effects of fluoxetine and imipramine on the phosphorylation of the transcription factor CREB and cell viability. J Psychiatr Res 2003;37:53–59.
7.
Koch JM, Kell S, Hinze-Selch D, Aldenhoff JB: Changes in CREB phosphorylation during recovery from major depression. J Psychiatr Res 2002;36:369–375.
8.
Besser M, Wank R: Cutting edge: clonally restricted production of the neurotrophins brain-derived neurotrophic factor and neurotrophin-3 mRNA by human immune cells and th1/th2-polarized expression of their receptors. J Immunol 1999;162:6303–6306.
9.
Bronzetti E, Artico M, Pompili E, Felici LM, Stringaro A, Bosco S, Magliulo G, Colone M, Arancia G, Vitale M, Fumagalli L: Neurotrophins and neurotransmitters in human palatine tonsils: an immunohistochemical and RT-PCR analysis. Int J Mol Med 2006;18:49–58.
10.
Kerschensteiner M, Gallmeier E, Behrens L, Leal VV, Misgeld T, Klinkert WE, Kolbeck R, Hoppe E, Oropeza-Wekerle RL, Bartke I, Stadelmann C, Lassmann H, Wekerle H, Hohlfeld R: Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation? J Exp Med 1999;189:865–870.
11.
Lommatzsch M, Zingler D, Schuhbaeck K, Schloetcke K, Zingler C, Schuff-Werner P, Virchow JC: The impact of age, weight and gender on BDNF levels in human platelets and plasma. Neurobiol Aging 2005;26:115–123.
12.
Pan W, Banks WA, Fasold MB, Bluth J, Kastin AJ: Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacology 1998;37:1553–1561.
13.
Gervasoni N, Aubry JM, Bondolfi G, Osiek C, Schwald M, Bertschy G, Karege F: Partial normalization of serum brain-derived neurotrophic factor in remitted patients after a major depressive episode. Neuropsychobiology 2005;51:234–238.
14.
Karege F, Bondolfi G, Gervasoni N, Schwald M, Aubry JM, Bertschy G: Low brain-derived neurotrophic factor (BDNF) levels in serum of depressed patients probably results from lowered platelet BDNF release unrelated to platelet reactivity. Biol Psychiatry 2005;57:1068–1072.
15.
Shimizu E, Hashimoto K, Okamura N, Koike K, Komatsu N, Kumakiri C, Nakazato M, Watanabe H, Shinoda N, Okada S, Iyo M: Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry 2003;54:70–75.
16.
Garcia-Suarez O, Blanco-Gelaz MA, Lopez ML, Germana A, Cabo R, Diaz-Esnal B, Silos-Santiago I, Ciriaco E, Vega JA: Massive lymphocyte apoptosis in the thymus of functionally deficient TrkB mice. J Neuroimmunol 2002;129:25–34.
17.
Weissman MM, Markowitz JC: Interpersonal psychotherapy: current status. Arch Gen Psychiatry 1994;51:599–606.
18.
Elkin I, Shea MT, Watkins JT, Imber SD, Sotsky SM, Collins JF, Glass DR, Pilkonis PA, Leber WR, Docherty JP, Fiester SJ, Parloff MB: National Institute of Mental Health Treatment of Depression Collaborative Research Program: General effectiveness of treatments. Arch Gen Psychiatry 1989;46:971–982; discussion 983.
19.
Blom MB, Jonker K, Dusseldorp E, Spinhoven P, Hoencamp E, Haffmans J, van Dyck R: Combination treatment for acute depression is superior only when psychotherapy is added to medication. Psychother Psychosom 2007;76:289–297.
20.
Gonul AS, Akdeniz F, Taneli F, Donat O, Eker C, Vahip S: Effect of treatment on serum brain-derived neurotrophic factor levels in depressed patients. Eur Arch Psychiatry Clin Neurosci 2005;255:381–386.
21.
Lee BH, Kim H, Park SH, Kim YK: Decreased plasma BDNF level in depressive patients. J Affect Disord 2007;101:239–244.
22.
Ziegenhorn AA, Schulte-Herbruggen O, Danker-Hopfe H, Malbranc M, Hartung HD, Anders D, Lang UE, Steinhagen-Thiessen E, Schaub RT, Hellweg R: Serum neurotrophins – a study on the time course and influencing factors in a large old age sample. Neurobiol Aging 2007;28:1436–1445.
23.
Kim YK, Lee HP, Won SD, Park EY, Lee HY, Lee BH, Lee SW, Yoon D, Han C, Kim DJ, Choi SH: Low plasma BDNF is associated with suicidal behavior in major depression. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:78–85.
24.
Lang UE, Bajbouj M, Gallinat J, Hellweg R: Brain-derived neurotrophic factor serum concentrations in depressive patients during vagus nerve stimulation and repetitive transcranial magnetic stimulation. Psychopharmacology (Berl) 2006;187:56–59.
25.
Tharmapathy P, Fukami MH, Holmsen H: The stimulatory effects of cationic amphiphilic drugs on human platelets treated with thrombin. Biochem Pharmacol 2000;60:1267–1277.
26.
Bockting CL, ten Doesschate MC, Spijker J, Spinhoven P, Koeter MW, Schene AH: Continuation and maintenance use of antidepressants in recurrent depression. Psychother Psychosom 2008;77:17–26.
27.
Cowan MJ, Freedland KE, Burg MM, Saab PG, Youngblood ME, Cornell CE, Powell LH, Czajkowski SM: Predictors of treatment response for depression and inadequate social support – the ENRICHED randomized clinical trial. Psychother Psychosom 2008;77:27–37.
28.
Scott J, Colom F: Gaps and limitations of psychological interventions for bipolar disorders. Psychother Psychosom 2008;77:4–11.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.